{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:07:29Z","timestamp":1791410849884,"version":"4.3.3"},"reference-count":21,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T00:00:00Z","timestamp":1370563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To evaluate the clinical efficacy and safety of intracoronary verapamil injection in the prevention and treatment of coronary no\u2010reflow after percutaneous coronary intervention (<jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Hypothesis<\/jats:title><jats:p>Intracoronary verapamil injection may be beneficial in preventing no\u2010reflow\/slow\u2010flow after PCI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched <jats:styled-content style=\"fixed-case\">PubMed<\/jats:styled-content>, Embase, and the Cochrane Central Register of Controlled Trials database. Randomized trials comparing the efficacy and safety of intracoronary verapamil infusion vs control in patients with acute coronary syndrome (<jats:styled-content style=\"fixed-case\">ACS<\/jats:styled-content>) were included. Meta\u2010analysis was performed by <jats:styled-content style=\"fixed-case\">RevMan<\/jats:styled-content> 5.0 software (Cochrane Collaboration, Copenhagen, Denmark) .<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven trials involving 539 patients were included in the analysis. Verapamil treatment was significantly more effective in decreasing the incidence of no\u2010reflow (risk ratio [<jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>]: 0.33; 95% confidence interval [<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>]: 0.23 to 0.50) as well as reducing the corrected thrombolysis in myocardial infarction (<jats:styled-content style=\"fixed-case\">TIMI<\/jats:styled-content>) frame count (<jats:styled-content style=\"fixed-case\">CTFC<\/jats:styled-content>) (weighted mean difference: \u221211.62; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: \u221216.04 to \u22127.21) and improving the <jats:styled-content style=\"fixed-case\">TIMI<\/jats:styled-content> myocardial perfusion grade (<jats:styled-content style=\"fixed-case\">TMPG<\/jats:styled-content>) (<jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>: 0.43; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.29 to 0.64). Verapamil also reduced the 30\u2010day wall motion index (<jats:styled-content style=\"fixed-case\">WMI<\/jats:styled-content>) compared to the control. Moreover, the procedure reduced the incidence of major adverse cardiac events (<jats:styled-content style=\"fixed-case\">MACEs<\/jats:styled-content>) in <jats:styled-content style=\"fixed-case\">ACS<\/jats:styled-content> patients during hospitalization (<jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>: 0.37; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.17 to 0.80) and 2\u2009months after <jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>: 0.56; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.33 to 0.95). However, administration of verapamil did not provide an additional improvement of left ventricular ejection fraction regardless of the time that had passed post\u2010<jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Intracoronary verapamil injection is beneficial in preventing no\u2010reflow\/slow\u2010flow, reducing <jats:styled-content style=\"fixed-case\">CTFC<\/jats:styled-content>, improving <jats:styled-content style=\"fixed-case\">TMPG<\/jats:styled-content>, and lowering <jats:styled-content style=\"fixed-case\">WMI<\/jats:styled-content>. It is also likely to reduce the 2\u2010month <jats:styled-content style=\"fixed-case\">MACEs<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">ACS<\/jats:styled-content> patients post\u2010<jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.22143","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T15:15:57Z","timestamp":1370618157000},"source":"Crossref","is-referenced-by-count":35,"title":["Short\u2010term Effect of Verapamil on Coronary No\u2010Reflow Associated With Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Systematic Review and Meta\u2010analysis of Randomized Controlled Trials"],"prefix":"10.1002","volume":"36","author":[{"given":"Qiang","family":"Su","sequence":"first","affiliation":[{"name":"Department of Cardiology The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular Institute  Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular Institute  Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangchun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular Institute  Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20634"},{"key":"e_1_2_6_3_1","first-page":"5","article-title":"No\u2010reflow phenomenon during percutaneous coronary intervention","volume":"26","author":"Chen Y","year":"2005","journal-title":"Adv Cardiovasc Dis."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016106776359835"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10375"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.06.015"},{"key":"e_1_2_6_8_1","first-page":"23","article-title":"Effect of intracoronary verapamil on no\u2010reflow during percutaneous coronary intervention","volume":"50","author":"Zhang H","year":"2010","journal-title":"Shangdong Med J."},{"key":"e_1_2_6_9_1","first-page":"32","article-title":"Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow","volume":"18","author":"Hendler A","year":"2006","journal-title":"J Invasive Cardiol."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00277-5"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.075077"},{"key":"e_1_2_6_12_1","first-page":"6","article-title":"Effect of intracoronary verapamil on coronary flow, myocardial perfusion and clinical outcome during percutaneous coronary intervention for acute myocardial infarction","volume":"17","author":"Qiao Z","year":"2009","journal-title":"Chin J Intervent Cardiol."},{"key":"e_1_2_6_13_1","first-page":"4","article-title":"Clinical efficacy and safety of intracoronary verapamil during percutaneous coronary intervention in patients with acute coronary syndromes","volume":"31","author":"Wu M","year":"2012","journal-title":"Chin J Geriatr."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.4.2593"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2007.08.005"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.06.090"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20183"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.3.239"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.18.2154"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.20010"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01138-X"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0304(199610)39:2<113::AID-CCD1>3.0.CO;2-I"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22143","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T01:50:59Z","timestamp":1696384259000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,7]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1002\/clc.22143"],"URL":"https:\/\/doi.org\/10.1002\/clc.22143","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,7]]}}}